Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jul 1;17:1533033818783450. doi: 10.1177/1533033818783450

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2018

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 1. — The consolidated standards of reporting trials diagram of this study of 182 patients with 229 tumors who underwent SBRT, 32 patients with 44 lesions, including 25 patients with 30 centrally located HCC who were selected 60 Gy dose in 8 fractions, 1 patients with 2 lesions who had dose constraints for gastrointestinal tract exposure, 1 patients with 1 lesion who was short follow-up periods (<6 months), and 5 patients with 11 lesions who received repeated SBRT with and without TACE were excluded from the analysis. Finally, 150 patients with 185 lesions who received 48 Gy in 4 fractions at the isocenter or 40 Gy in 4 or 5 fractions at the D95% of the PTV were analyzed. D_95% indicates the dose covering 95% of the PTV; HCC, hepatocellular carcinoma; PTV, planning target volume; SBRT, stereotactic body radiotherapy.